SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC the metals company Inc. is trending after recent regulatory updates from NOAA allowed its US subsidiary to submit a consolidated application for an expanded deep-sea exploration and commercial recovery permit, streamlining the path to critical mineral production. The community is highly bullish, anticipating rapid permit approval and significant government backing due to national security implications and the urgent need for domestic supply of EV and low-carbon energy metals, with discussions frequently highlighting substantial upside and a potential short squeeze.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is gaining attention due to recent advancements in its pipeline, including significant progress in tecarfarin manufacturing and a collaboration with Abbott for its pivotal Phase 3 trial targeting LVAD patients. While some investors are optimistic about its potential in the anticoagulation market, community sentiment also highlights concerns around the company's cash position, recent offerings, and the notable presence of bot activity amplifying its trend.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is generating significant buzz following reports of a substantial planned investment from the US government, which includes an equity stake aimed at strengthening the domestic rare earth supply chain. This is further amplified by news of an upcoming rare earth metals and alloys production facility in France, bolstered by government support. The community is actively discussing the potential for a massive stock surge and a short squeeze, reflecting strong sentiment around the company's strategic importance in securing critical mineral resources.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

DOG CRYPTO is trending amidst strong community excitement, primarily driven by rumors of a Coinbase listing and increasing institutional interest, with C2 Blockchain notably expanding its holdings. Enthusiasts are actively promoting it as the leading Bitcoin-native memecoin, emphasizing its fixed supply and decentralized nature as superior to other meme tokens and expressing high conviction for its long-term growth and potential to outperform.

The White Whale

WHITEWHALE is experiencing active community discussion around recent price volatility, with some attributing it to market manipulation and large-scale profit-taking. Despite this, a strong bullish sentiment persists, fueled by significant token burns, a substantial portion of supply locked long-term, and consistent growth in its holder base. The community largely views current dips as accumulation opportunities, reinforcing its belief in the token's long-term potential and legitimacy.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as intense debate erupts over a recent fatal shooting involving federal agents in Minneapolis. Community members are sharply divided, with some condemning the incident as an unjustified act against a citizen and others defending the agents' response to alleged interference with federal operations. This contentious event fuels broader discussions about federal authority and political polarization, potentially impacting ongoing government funding debates.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is actively discussed as a quantum computing leader following significant accumulation by institutional investors like BlackRock and its strategic advancement in government contracts. The company recently secured a $21.1 million Air Force project and joined the "Golden Dome" initiative, positioning itself as a full-stack quantum infrastructure provider, while its presence at CES 2026 highlights its commitment to commercial applications and ongoing community excitement.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending following its mainnet migration to an EVM-compatible L2 on Arbitrum Orbit, positioning $JASMY as a custom gas token for AI and Web3 applications. This significant development has sparked intense debate, with many community members highlighting its foundational utility and regulatory backing in Japan as catalysts for a potential surge, while skeptics point to historical volatility and recent price action as typical 'pump and dump' behavior.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the following segments: Advanced Technology Solutions (ATS), and Connectivity and Cloud Solutions (CCS). The Advanced Technology Solutions (ATS) segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The Connectivity and Cloud Solutions (CCS) segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is trending due to recent market reports suggesting a potential shift in a major customer's assembly work, which many in the community are actively debating as a strategic play to acquire shares at a lower valuation. Despite this volatility, investors are highlighting the company's strong fundamentals and critical role in the expanding AI and data center infrastructure, with high anticipation for its upcoming earnings report to reaffirm its market leadership.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. ($BNAI) is trending due to intense community speculation around a significant short squeeze, fueled by a recent AI licensing deal and notable volume. Discussions highlight the stock's low float and high borrow rates, leading to widespread anticipation of further pressure on short sellers. The conversation actively buzzes with comparisons to past high-flying short squeeze events within the broader AI sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best Pharmaceutical Stocks To Add to Your Watchlist - January 24th

Eli Lilly and Company, Abbott Laboratories, Gilead Sciences, Novo Nordisk A/S, AbbVie, Pfizer, and Vertex Pharmaceuticals are the seven Pharmaceutical stocks to watch today, according to MarketBeat's...

<ul class="summary-bullets"><li>Reuters noted that oral Wegovy’s debut is stronger than observed with Novo’s injectable Wegovy or its rival Eli Lilly and Company’s Zepbound.&nbsp;</li><li>Novo’s rival Lilly, meanwhile, is looking forward to getting FDA approval for its oral obesity drug Orforglipron by April.</li></ul>Danish drugmaker Novo Nordisk’s (NVO) Wegovy pill reportedly hit over 18,000 U.S. prescriptions in the first full week after its launch, marking a strong start for the oral weight-loss pill. &nbsp;Reuters <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/novos-wegovy-pill-tracks-18410-prescriptions-first-full-week-since-launch-2026-01-23/">reported</a> on Friday, citing IQVIA data shared by analysts, that Novo’s weight-loss pill was prescribed 18,410 times in the week ended January 16. As per the report, this is a stronger debut than observed with Novo’s injectable Wegovy or its rival Eli Lilly and Company’s Zepbound.Last week, it was reported that the Wegovy pill hit 3,071 U.S. prescriptions in just the first four days after its launch on Jan 5.NVO shares traded marginally in the green on Friday at the time of writing.<h2 class="st-heading-2">Wegovy Pill Approval</h2>Oral obesity pills are expected to be the next major innovation in the obesity market, doing away with needles and offering customers more flexibility and ease.The U.S. Food and Drug Administration (FDA) approved the Wegovy pill to reduce body weight and maintain weight reduction for a longer term in December.The Wegovy pill is now the first FDA-approved oral GLP-1 class drug for weight management and marks a crucial step forward for the company in its ongoing efforts to protect market share from rival Eli Lilly, whose injectable GLP-1 drug Zepbound is fast taking over Wegovy’s market dominance. The company launched the Wegovy pill earlier this month, starting at $149 a month.Novo’s rival Lilly, meanwhile, is looking forward to getting FDA approval for its oral obesity drug Orforglipron by April. Novo now has a few months’ head start against Lilly to cement its customer base.On Thursday, Goldman Sachs raised its price target on Novo Nordisk to DKK 436 from DKK 352 while keeping a ‘Buy’ rating on the shares. The firm believes investor focus in the first half of 2026 will be the launch for Novo's Wegovy pill. The weight loss pill should contribute to positive earnings momentum in the near term, the analyst told investors, as per TheFly.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NVO stock stayed within the ‘bullish’ territory, while message volume fell from ‘high’ to ‘normal’ levels.<a href="https://stocktwits.com/symbol/NVO">NVO shares</a> have fallen 23% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/bhc-stock-plummets-on-failed-liver-cirrhosis-trial/cmyRgOmR4gz">Tesla’s Market Share Dives In EV Stronghold California In 2025, Paving Way For Asian Rival’s Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk In Green After Oral Wegovy Clocks Over 18K Prescriptions In A Week

Reuters reported on Friday, citing IQVIA data shared by analysts, that Novo’s weight-loss pill was prescribed 18,410 times in the week ended January 16.

Equity

Reuters reported on Friday, citing IQVIA data shared by analysts, that Novo’s weight-loss pill was prescribed 18,410 times in the week ended January 16.


Top Pharmaceutical Stocks To Watch Now - January 23rd

Eli Lilly and Company, Abbott Laboratories, Novo Nordisk A/S, Gilead Sciences, Pfizer, AbbVie, and Alnylam Pharmaceuticals are the seven Pharmaceutical stocks to watch today, according to...

Best Medical Stocks To Keep An Eye On - January 23rd

UnitedHealth Group, Eli Lilly and Company, Abbott Laboratories, Novo Nordisk A/S, Thermo Fisher Scientific, Gilead Sciences, and Intuitive Surgical are the seven Medical stocks to watch today...

Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?

Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Vantage Investment Partners LLC Acquires 79,441 Shares of Novo Nordisk A/S $NVO

Vantage Investment Partners LLC boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 17.5% in the third quarter, according to the company in its most recent Form 13F filing...

Northstar Asset Management Inc. Raises Position in Novo Nordisk A/S $NVO

Northstar Asset Management Inc. raised its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 31.1% during the third quarter, according to its most recent filing with the Securities and...

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in San Francisco...

QV Investors Inc. Increases Position in Novo Nordisk A/S $NVO

QV Investors Inc. raised its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 76.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange...

Hara Capital LLC Invests $2.58 Million in Novo Nordisk A/S $NVO

Hara Capital LLC bought a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm bought 46,417 shares of the...

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

$MSFT

$AAPL

$TSLA

$META

Earnings season is heating up, and several major companies report next week, including Microsoft, Apple, Tesla, and Meta. Which are you most excited for?

Which earnings report are you most excited for next week? 
 
Drop a comment for others.

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NVO News

NVONovo Nordisk A/S